Looking Beyond Today’s Rare Kidney Successes to Identify the Next High-Value Indications & Expand Therapeutic Innovation
2:00 pm - Tuesday 16th March 2027
- Prioritizing Alport syndrome, FSGS, membranous nephropathy, congenital kidney disease and other underserved populations
- Translating successful mechanisms from crowded indications into diseases sharing relevant biology
- Defining where industry should focus next as IgAN becomes increasingly competitive